<DOC>
	<DOCNO>NCT00350753</DOCNO>
	<brief_summary>Erlotinib bevacizumab show activity individually , single drug , combination chemotherapy upper gastro-intestinal cancer , include esophageal gastro-esophageal adenocarcinoma , gastric cancer pancreatic cancer . Biomarkers indicate important role EGF VEGF find tumor , cholangiocarcinomas well . There promise combine treatment erlotinib bevacizumab active tolerable broad range upper gastro-intestinal cancer , justify experimental phase II-study patient diagnosis , refractory intolerant standard systemic therapy .</brief_summary>
	<brief_title>Avastin Tarceva Upper Gastrointestinal Cancers</brief_title>
	<detailed_description>Primary Objective - To determine median time progression ( TTP ) response rate ( RR ) combination erlotinib bevacizumab patient advance upper gastro-intestinal carcinoma , refractory intolerant standard systemic therapy . Secondary Objective - To determine safety , tolerability toxicity . - To determine median overall survival ( OS ) . - To correlate efficacy treatment expression tumor marker obtain serum ( EFGR , bFGF , p-VEGF-A , sVEGF-R2 ) , paraffin embed tumor tissue ( micro vessel density ( MVD ) , expression VEGFR EGFR , immunostaining ) , fresh frozen tumor biopsy ( micro array-based analysis pattern gene expression ) . Treatment : Bevacizumab ( Avastin√í ) give intravenously 10 mg/kg every week . Erlotinib give orally daily dose take least one hour two hour ingestion food .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically verify carcinoma gall bladder bile duct . PS 01 ( ECOG scale ) Age &gt; 18 year Life expectancy &gt; 3 month Sufficient organ function , define : Platelets &gt; 100 x 109/liter Leukocytes &gt; 3,0 x 109/liter ACN &gt; 1,5 x 109/liter ASAT and/or ALAT &lt; 3 x upper normal limit Bilirubin &lt; 1,5 x upper normal limit EDTA clearance &gt; 45 ml/min APTT INR &lt; normal limit Fertile female must use oral contraceptive , IUD ( intrauterine device ) preservatives . Fertile male must use preservative . Radiotherapy chemotherapy within last 4 week Comedication may interfere study result ; e.g . immunosuppressive agent corticosteroid Any prior EGFR VEGFRbased therapy Any condition ( medical , social , psychological ) , would prevent adequate information followup Tumor locate close major blood vessel judge possess high risk serious bleed Any active malignancy , except basal squamous cell carcinoma skin , carcinoma situ Any significant cardiac disease ( New York Heart Association Class II great ) , significant arrythmia , congestive heart failure , acute myocardial infarction within 6 month unstable angina pectoris Clinically significant peripheral vascular disease Evidence coagulopathy Use ASA , NSAIDs clopidogrel Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior treatment , anticipation need major surgical procedure curse study Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior treatment History abdominal fistula , gastrointestinal perforation intraabdominal abscess within 6 month prior treatment Any ongoing infection , uncontrolled diabetes mellitus , serious nonhealing wound ulcer Pregnancy breast feed Ongoing therapeutic anticoagulation Hypertension blood pressure &gt; 150/100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
</DOC>